CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Agenus BOT+BAL meets primary endpoint in Phase 2 MSS colon cancer trial

By Public Technologies
  • Agenus announced published Phase 2 UNICORN results in Nature Medicine evaluating preoperative botensilimab plus balstilimab in resectable, locally advanced colon cancer.
  • The combination produced deep tumor responses, including complete tumor clearance in some patients with microsatellite-stable disease, which historically resisted conventional immunotherapy.
  • No combination-treated patients experienced cancer recurrence by the February 9, 2026, data cutoff; all trial participants underwent surgery.
  • The findings support the planned randomized Phase 3 ROBBIN trial comparing the combination followed by standard care against standard care alone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611020642BIZWIRE_USPR_____20261102_BW365981) on November 02, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk